Marius Pharmaceuticals, a company dedicated to developing therapies for testosterone deficiency, has launched a pilot study focusing on the effects of its oral testosterone therapy, KYZATREX (testosterone undecanoate), on male fertility, specifically spermatogenesis. KYZATREX, approved for testosterone replacement therapy in adult males with testosterone deficiency, will be the subject of this pioneering study. The study aims to explore how this oral testosterone…
ReproTech, a company in the field of cryogenic storage of human reproductive tissue, has announced the launch of its new subsidiary, Cryo-Logix. The initiative aims to provide In vitro fertilization (IVF) clinics with a comprehensive end-to-end cryostorage solution, addressing a long-standing need in the fertility sector. Cryo-Logix emerges as a separate entity under the ReproTech umbrella, with a dedicated focus on enhancing…
In a recent somewhat buzzworthy Bloomberg report, fertility scale-up Kindbody, a trailblazer and well-known unicorn in the femtech world, has come under scrutiny for allegedly nudging its doctors to ramp up egg retrievals — all in the pursuit of beefier profitability margins and the alluring prospect of an IPO. While Kindbody’s growth tactics are currently center stage, it’s crucial to see this…
At the close of the previous year, Manina Medtech, a spin-off from the Vall d’Hebron Institute of Research (VHIR), secured €1.75M in funding to support the development and clinical trials of their new medical device, SEEDCHRONY. This device is positioned to advance In Vitro Fertilization (IVF) outcomes by improving embryo implantation processes. The funding round included significant investments from a consortium of…
TMRW Life Sciences, known for its automation technology in IVF labs, has announced its expansion into the United Kingdom. This strategic move introduces the company’s advanced CryoRobot Select (CRS) system to the UK market, starting with The Hewitt Fertility Centre in Liverpool. The CRS system automates the storage and management of frozen eggs and embryos, aiming to enhance safety and efficiency in…
Mosie Baby, an at-home fertility care company, has recently obtained FDA Class II clearance for its Mosie Baby Kit. This clearance positions the Mosie Baby Kit as the first and only over-the-counter option for intravaginal insemination (IVI) approved by the FDA. The kit was developed to help individuals and couples who face challenges with natural conception or for whom traditional intercourse is…
MIM Fertility, a Polish company in the field of artificial intelligence, has announced the closing of a $2M seed funding round. The investment was led by Warsaw-based venture capital investors, Tangent Line and Peleton. MIM Fertility offers solutions in infertility treatment, combining advanced artificial intelligence technologies with reproductive medicine. Their flagship products, EMBRYOAID and FOLLISCAN help experts in the identification and analysis…
Orchid, a reproductive technology company, has announced the introduction of the world’s first 30x whole genome sequencing reports for embryos. This innovation, supported by a $12M in total funding, is set to provide prospective parents with unprecedented insights into the genetic health of embryos. Orchid’s investors include Prometheus Fund, Starbloom Capital, Refactor Capital, Pebblebed, Day One Ventures, and Conviction Capital, as well…
